N/A N=46 Computerized Cognitive Training in Breast Cancer Survivors
Breast Cancer · Cognitive Change · Cognitive Impairment
Primary: Client Satisfaction Questionnaire — 29.7; 27.9 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=226 EGb761 in Maintaining Mental Clarity in Women Receiving Chemotherapy for Newly Diagnosed Breast Cancer
Breast Cancer · Neurotoxicity
Primary: The Level of Cognitive Dysfunction as Measured by the High Sensitivity Cognitive Screen (HSCS) Overall Score. — 12.2; 12.6; 3.9; 2.6 units on a scale*months — p=0.84
N/A N=45 Electrophysiological Biomarkers of Chemotherapy-related Cognitive Impairment and Recovery
Myelodysplastic Syndrome · Effects of Chemotherapy · Mild Cognitive Impairment
Primary: Change From Baseline Capture Task Performance at 1- and 3- Months — .103; -.039; .066; .067 change in proportional response time
Phase 2 N=51 Memantine for Prevention of Cognitive Decline in Patients With Breast Cancer
Cognitive Decline · Chemo-brain
Primary: Change in Visual Working Memory - Delayed Matching to Sample Test — 16; 13; 16 Participants
Phase 2 N=62 Study of Donepezil in Female Breast Cancer Survivors With Cognitive Dysfunction
Anxiety Disorder · Breast Cancer · Cognition Disorders
Primary: Retention — 71.0; 80.7 percentage of participants
Phase 2 N=22 Nicotinic Treatment of Post-Chemotherapy Subjective Cognitive Impairment: A Pilot Study
Chemo Brain · Chemotherapy-related Cognitive Impairment · Chemo Fog
Primary: Change in the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) PCI Scale — 7.00; 11.55; 16.80; 16.64 units on a scale — p==0.41
N/A N=87 Physical Activity and Neuropsychological Outcomes in a Cancer Population
Cognitive Dysfunction · Breast Cancer Survivors
Primary: National Institutes of Health Toolbox - Cognition Domain- Oral Symbol Digit Test — 7; 3 units on a scale — p=<0.05
N/A N=47 The "Light for the Brain" Study
Hematopoietic Stem Cell Transplantation · Cognitive Impairments · Sleep
Primary: Cognitive Functioning (Neuropsychological Tests) — 0.24; 0.16; 0.43; 0.50 z-score
N/A N=12 Feasibility of the Memory and Attention Adaptation-Training Geriatrics Intervention in Older Cancer Survivors With Mild Cognitive Impairment
Cognitive Dysfunction
Primary: MAAT-G Feasibility Completion Rate — 10 Participants
N/A N=72 Memory and Attention Adaptation Training-Geriatrics (MAAT-G) Phase II
Cancer-related Problem/Condition · Cognitive Impairment
Primary: Mean of the Functional Assessment of Cancer Therapy-Cognition (FACT-COG) — 155.8; 152.7 score on a scale
N/A N=153 Exercise Program in Cancer and Cognition
Breast Cancer
Primary: Change in Cognitive Function — -0.05; 0.01; 0.21; 0.17 z-score
Phase 4 N=469 Learning Impairments Among Survivors of Childhood Cancer
Acute Lymphoblastic Leukemia · Brain Tumors
Primary: Brain White Matter Volume for Patients Versus Sibling Controls — 27; 30.3 percentage — p=<.0001
Phase 3 N=276 Phase 3 Randomized Placebo Controlled Clinical Trial of Donepezil
Cognitive Dysfunction · Memory Impairment
Primary: Hopkins Verbal Learning Test-Revised (HVLT-R) - Total — 24.4; 24.5; 26.0; 26.5 score on a scale of 0-36 — p=0.32
N/A N=5 Memory and Attention Adaptation Training-Geriatrics (MAAT-G)
Cancer-related Problem/Condition · Cognitive Impairment
Primary: System Usability Scale (SUS) — 90.6 score on a scale
Phase 3 N=86 Brain Function in Premenopausal Women Receiving Tamoxifen With or Without Ovarian Function Suppression for Early-Stage Breast Cancer on Clinical Trial IBCSG 24-02
Breast Cancer · Fatigue · Sleep Disorders
Primary: Change in Cognitive Function Over 1 Year in Premenopausal Breast Cancer Patients Who Receive Adjuvant Tamoxifen (T) Alone Against Those Receive Adjuvant Tamoxifen…
Phase 2 N=32 Trial of Mesna to Prevent Doxorubicin-induced Plasma Protein Oxidation and Tumor Necrosis Factor Alpha (TNF-α) Release
Breast Cancer · Non-Hodgkin's Lymphoma
Primary: TNF-alpha Levels in Patients Receiving Doxorubicin Containing Chemotherapy — 3.55; 3.68; 2.95; 3.18 log(pg/ml) — p=0.014
N/A N=45 Computer Training Program for Younger Patients With a Brain Tumor Who Underwent Radiation Therapy
Brain Neoplasm · Recurrent Brain Neoplasm
Primary: Intervention Compliance — 0.39; 0.50 Proportion of Participants
Early Phase 1 N=36 COGNUTRIN in Breast Cancer Survivors
Breast Cancer
Primary: Change in Cognitive Function Scores With Intervention - HVLT and COWA — 49.04; 44.93; 42.28; 43.33 score
Phase 2 N=19 CDP-Choline and Working Memory After TBI: A Neuroimaging Study
Brain Injuries
Primary: Cognitive Composite Score for Group of Subjects With TBI and Healthy Controls Matched by Age, Education, and Treatment Group. — 42.750; 50.500; 49.500; 55.000 T-score…
Phase 3 N=518 Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases
Cognitive Impairment · Metastatic Malignant Neoplasm in the Brain · Solid Neoplasm
Primary: Time to Neurocognitive Failure — 68.2; 59.3 percentage of participants — p=0.029
Phase 2 N=96 Cognitive Behavioral Therapy +/- Armodafinil for Insomnia and Fatigue Following Chemotherapy
Insomnia · Fatigue · Breast Cancer
Primary: Change in Insomnia Severity Index From Baseline to Post-intervention — -4.93; -6.36; 1.04; -1.43 units on a scale
N/A N=45 Metacognitive Strategy Training in Cancer-related Cognitive Impairment
Breast Cancer Female
Primary: Telehealth Usability Questionnaire (TUQ) — 6.38; 6.31 units on a scale
Phase 2 N=73 Cognitive Stimulation
Substance Use Disorders
Primary: Working Memory — 0.86; 0.04 digits recalled
Phase 3 N=198 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors
Brain Tumors · Metastatic Disease
Primary: Memory as Quantified by HVLT-immediate Recall — 22.5; 22.2 units on a scale — p=.62
N/A N=39 Effect of Increased Light Exposure on Fatigue in Breast Cancer
Breast Cancer
Primary: Fatigue — 15.25; 21.6 units on a scale
N/A N=12 Brain Stimulation and Cognitive Training
Bipolar Disorder · Schizo Affective Disorder · Schizophrenia
Primary: Participant Retention in Combination Treatment — 4; 5 Participants
N/A N=33 Treatment for Executive Dysfunction in Adult Survivors of Childhood Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia
Primary: Feasibility of At Home tDCS Intervention — 25 Participants
Phase 2 N=97 The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients
Cancer-related Cognitive Difficulties
Primary: Memory Performance as Assessed by Computerized Cognitive Assessment - Mean Values by Arm — 75.2; 82.7; 83.6; 74.3 % correct — p=0.9168
Phase 3 N=161 Cranial Stimulation for Chemotherapy Symptoms in Breast Cancer
Anxiety Disorder · Breast Cancer · Depression
Primary: Effects of CES as Compared to Sham CES on Symptoms of Depression, Anxiety, Fatigue, Pain and Sleep Disturbances in Women Receiving Adjuvant Chemotherapy for Early-stage…
Phase 2 N=75 Testing Ramipril to Prevent Memory Loss in People With Glioblastoma
Glioblastoma · Radiotherapy; Complications · Cognitive Decline
Primary: Change From Baseline Neurocognitive Function at 10 Weeks - Hopkins Verbal Learning Test-Revised (HVLT-R) Total Recall Standardized Score — 0.09; -0.40 Change in…